Straits Times Index
3,309.57 -12.51 (-0.38%) Nikkei
39,147.32 +109.16 (+0.28%) Hang Seng
18,065.47 -301.48 (-1.64%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
68,011.97 -1,744.95 (-2.50%) CMC Crypto 200
1,413.50 -33.17 (-2.29%)
BIIB Jan 2025 210.000 put
| Previous close | 11.50 |
| Open | 12.10 |
| Bid | 10.00 |
| Ask | 13.00 |
| Strike | 210.00 |
| Expiry date | 2025-01-17 |
| Day's range | 11.50 - 12.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 624 |
Yahoo FinanceFDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
An FDA panel voted unanimously to support Eli Lilly's Alzheimer's drug for use in adults 60-85 years old.
ZacksBiogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.
GlobeNewswireFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. A Prescription Drug Us
